Lupin Launches Raltegravir Tablets in US with 180-Day Generic Exclusivity
Lupin Ltd 路 Press Release 路 04 Nov 2026, 1:08 am
Lupin Launches Raltegravir Tablets in US with 180-Day Generic Exclusivity Lupin Limited has launched Raltegravir Tablets USP, 600 mg in the US following US FDA approval for its ANDA. The product is bioequivalent to Merck Sharp & Dohme's reference listed drug Isentress HD Tablets, 600 mg, indicated for HIV-1 treatment. As the exclusive first-to-file applicant, Lupin is eligible for 180-day generic drug exclusivity. According to IQVIA MAT Sep'26 data, Raltegravir Tablets USP, 600 mg recorded estimated annual US sales of USD 26 million.
Original exchange filing (PDF)
More announcements from Lupin Ltd
- Lupin Announces European Launch of Biosimilar Ranibizumab. 路 12 Nov 2026
- Transcript of Q2 FY2027 Earnings Conference Call. 路 07 Nov 2026
- Link of Audio recording of the Earnings Call-Q2 FY27. 路 05 Nov 2026
- Investor Presentation- Q2 FY2027 路 04 Nov 2026
- Lupin Q2 FY2027 Results 路 04 Nov 2026
- Appointment of Mr. Akhil Gupta as an Additional Director (Non-Executive, Independent) effective November 03, 2026 and as an Independent Director for a term of five consecutive years with .... 路 04 Nov 2026
- Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2026. 路 04 Nov 2026
- Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2026. 路 04 Nov 2026
